PCa Commentary # 146: Radium-223 (Xofigo); A Radioisotope Treatment for Prostate Cancer Metastatic to Bone. The radiobiology of Radium-223 suggests greater effectiveness when used early in metastatic castration-resistant prostate cancer (mCRPC).

by Dr. Ed Weber | Oct 7, 2020 | PCa Commentary

In 2013 Radium-223 was FDA approved for treatment of prostate cancer patients with bone metastases on the basis of a large randomized trial, ASYMPCA, comparing the radioisotope to a placebo. In 708 heavily pretreated men, the overall median survival was extended by...

PCa Commentary # 145: PSA, PSA Dynamics, and Advances in Imaging: PSA and the PSADT (PSA doubling time) Guide the Management of Prostate Cancer.

by Dr. Ed Weber | Oct 7, 2020 | PCa Commentary

Following radical prostatectomy [and radiation therapy] for organ confined disease, approximately one-third of men will develop a biochemical relapse with a detectable PSA level.”  Quoted from “PSA Doubling Time and Absolute PSA Predict Metastases-free Survival in Men...

PCa Commentary #144: THE CHECKPOINT INHIBITORS – In Search of a Role in the Treatment of Prostate Cancer: The Current Status.

by Dr. Ed Weber | Sep 1, 2020 | PCa Commentary

PCa Commentary #143: ANTI-PSMA 177-LUTETIUM RADIOLIGAND THERAPY: An Update on Outcomes; the Vision Trial; and Future Directions

by Dr. Ed Weber | Feb 26, 2020 | PCa Commentary

Three new modalities for treatment of advanced prostate cancer are in development that will significantly impact management and extend overall survival:  immunotherapy with checkpoint blockade;  poly ADP-ribosepolymerase (PARP) inhibitors; and  anti-PSMA radioligand...

PCa Commentary #142 ANTI TUMOR IMMUNE RESPONSE POTENTIATED by RADIOTHERAPY: A concept arising from pre clinical studies now is clinically supported by the results of the ORIOLE trial.

by Dr. Ed Weber | Feb 4, 2020 | PCa Commentary

The ORIOLE TRIAL, “Primary Outcomes of a Phase II Randomized Trial of Observation Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancer,” Phillips et al., Int. J. Radiation Oncology Biology Physics, November 1, 2019 The study had two...

PCa Commentary #141 PARP INHIBITION THERAPY Clinical Importance of genetic variants of BRCA 1/2 and ATM in men with metastatic castration resistant prostate cancer.

by Dr. Ed Weber | Jan 21, 2020 | PCa Commentary

Something big is emerging in the management of men with metastatic (often heavily pre-treated) castration-resistant prostate cancer. A potentially new entry into the regimens of standard-of-care i.e., treatment of men with BRCA 1/2 and ATM mutations with PARP...